ArticleApplied microbiology and biotechnology2020
Targeting staphylocoagulase with isoquercitrin protects mice from Staphylococcus aureus-induced pneumonia.
Article in Applied microbiology and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- A Polyphenol-Rich Diet Increases the Gut Microbiota Metabolite Indole 3-Propionic Acid in Older Adults with Preserved Kidney Function.Molecular nutrition & food research · 2022Trial
- Exploring the antibacterial mechanism and biofilm inhibition ofCurrent research in food science · 2026Article
- Chemical Profiling and Multi-Target Bioactivities of Erodium guttatum From Northeastern Algeria: LC-MS/MS and Molecular Docking Insights.Chemistry & biodiversity · 2026Article
- DisarmingPathogens (Basel, Switzerland) · 2025Review
- Synthesis and antimicrobial activity evaluation of pyrazole derivatives containing imidazothiadiazole moiety.Future medicinal chemistry · 2025Article
- Antibacterial and antibiofilm activities and mechanisms ofCurrent research in food science · 2025Article
- Article
- Thwarting resistance: MgrA inhibition with methylophiopogonanone a unveils a new battlefront against S. aureus.NPJ biofilms and microbiomes · 2024Article
- Bilobetin attenuates Staphylococcus aureus virulence by targeting Von Willebrand factor-binding protein and staphylocoagulase.World journal of microbiology & biotechnology · 2023Article
- PhytoestrogenVaccines · 2023Article
- Polyphenols as Inhibitors of Antibiotic Resistant Bacteria-Mechanisms Underlying Rutin Interference with Bacterial Virulence.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Potential Mechanisms of Quercetin Influence the ClfB Protein During Biofilm Formation ofFrontiers in pharmacology · 2022Article
- Isovitexin Is a Direct Inhibitor ofJournal of microbiology and biotechnology · 2021Article
- Inferring multilayer interactome networks shaping phenotypic plasticity and evolution.Nature communications · 2021Article
- cydA, spdC, and mroQ are novel genes involved in the plasma coagulation of Staphylococcus aureus.Microbiology and immunology · 2021Article
- Polyphenol-RichAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Staphylocoagulase (Coa) is a virulence factor of Staphylococcus aureus (S. aureus) that promotes blood coagulation by activating prothrombin to convert fibrinogen to fibrin. Coa plays a crucial role in disease pathogenesis and is a promising target for the treatment of S. aureus infections. Here, we identified that isoquercitrin, a natural flavonol compound, can markedly reduce the activity of Coa at concentrations that have no effect on bacterial growth. Mechanistic studies employing molecular dynamics simulation revealed that isoquercitrin binds to Coa by interacting with Asp-181 and Tyr-188, thereby affecting the binding of Coa to prothrombin. Importantly, in vivo studies showed that isoquercitrin treatment significantly reduced the bacterial burden, pathological damage, and inflammation of lung tissue and improved the percentage of survival of mice infected with S. aureus Newman strain. These data suggest that isoquercitrin is a promising inhibitor of Coa that can be used for the development of therapeutic drugs to combat S. aureus infections.Key Points• Staphylocoagulase plays a key role in the pathogenesis of S. aureus infection.• We identified that isoquercitrin is a direct inhibitor of staphylocoagulase.• Isoquercitrin treatment can significantly attenuate S. aureus virulence in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.